Company news: Pfizer and Bristol-Myers Squibb

The FDA granted priority review status to Eliquis (apixaban), the novel oral anticoagulant being developed by Pfizer and Bristol-Myers Squibb, the firms said. The PDUFA goal date for a decision by the FDA is March 28, 2012.

The FDA issued a draft Blueprint for educating doctors on opioid drugs including long-acting and extended-release brand name and generic products. The blueprint contains core messages intended for use by continuing education providers to develop educational materials to train prescribers under the required risk evaluation and mitigation strategy (REMS) for these products. The FDA is seeking stakeholder input on the document until December 7.

You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.